However, EML4‐ALK V3‐positive NSCLC patients demonstrate a higher metastatic spread and increased aggressiveness of the disease, while in vitro NSCLC cells harbouring EML4‐ALK V3 exhibit resistance to various ALK inhibitors (Woo et al, 2017; Christopoulos et al, 2018; O'Regan et al, 2020). This evidence concerns the gene EML4 and non-small cell lung carcinoma.